U.S. Hemovigilance Program Aims To Improve Safety, Reduce Costs
Prior to the establishment of the new National Hemovigilance Program in February, 2010, the U.S. was the only developed country without an established method to nationally track and aggregate adverse events associated with blood transfusions.
The program is part of the National Healthcare Safety Network of the Centers for Disease Control (CDC), and allows all U.S. hospitals that transfuse blood and blood products to enroll and contribute data on adverse events associated with blood transfusions.
The Hemovigilance Program is a component of the U.S. Biovigilance Network. Data collected and analyzed by this new program is expected to improve patient safety and reduce U.S. healthcare costs.
If your organization is interested in participating, click here for the Intent to Participate Form.
Janet DiMaggio says:
June 20th, 2011 at 1:59 pm
I work in the pharmaceutical industry with biologics. I am looking for any training or seminars which could benefit me in my job related to the evaluation of Lookbacks. I am the contact person responsible for receiving notification from the blood bank for potentially tainted or infected blood (red blood cells) used in the manufacturing of our Product. I sometimes need to make a decision based upon the BB information and the manufacturing process.
Thank-you